BACE2 and Alzheimer disease: None of the kinetic parameters discussed in the present section and illustrated in Figure 13 have a conceptual impact on the proposed therapeutic strategy at symptomatic stages of AD, namely the iAβ depletion via its targeted degradation by the Aβ-cleaving activities of BACE1 and/or BACE2 or by any other suitable agent.